Fethiye State Hospital, Department of Biochemistry - Muğla, Turkey.
Konya City Hospital, Department of Biochemistry - Konya, Turkey.
Rev Assoc Med Bras (1992). 2022 Jun 24;68(6):814-819. doi: 10.1590/1806-9282.20220153. eCollection 2022.
Hypertension is a major modifiable risk factor for cardiovascular disease and premature death worldwide. Phoenixin is a newly identified neuropeptide with multiple bioactivity. However, there was no published data about phoenixin levels in hypertension. The aim of this study was to evaluate the relationship between phoenixin and hypertension.
This study was performed in 36 patients with hypertension and 36 healthy controls. Serum phoenixin-14 and phoenixin-20 levels were determined by Enzyme-Linked ImmunoSorbent Assay method.
Serum phoenixin-14 and phoenixin-20 values were significantly lower in hypertension patients compared with the control group (p<0.001). The levels of phoenixin-14 were negatively correlated with weight (r=-0.376; p<0.005), body mass index (r=-0.407; p<0.001), systolic blood pressure (r=-0.586; p<0.001), and diastolic blood pressure (r=-0.319; p<0.01). There was a negative correlation between serum phoenixin-20 and weight (r=-0.378; p<0.005), body mass index (r=-0.383; p<0.005), systolic blood pressure (r=-0.551; p<0.001), and diastolic blood pressure (r=-0.306; p<0.01). We used receiver operating characteristic curve analyses to compare the diagnosis value of Phoenixin-14 and Phoenixin-20 levels in hypertensive patients. We found that Phoenixin-14 value is an area under the curve of 0.87 (cutoff value 404.7 ng/L, sensitivity 92%, specificity 72%) and Phoenixin-20 value is an area under the curve of 0.83 (cutoff value 209.9 ng/L, sensitivity 86%, specificity 75%). Phoenixin-14 did nearly show equally compared to phoenixin-20 in predicting hypertension.
Serum phoenixin-14 and phoenixin-20 may be related to the pathogenesis of hypertension. Our findings indicated that serum phoenixin-14 and phoenixin-20 may serve as a novel biomarker for the diagnosis of hypertension.
高血压是全球心血管疾病和过早死亡的主要可改变风险因素。凤凰素是一种新发现的具有多种生物活性的神经肽。然而，目前尚无关于高血压患者凤凰素水平的发表数据。本研究旨在评估凤凰素与高血压之间的关系。
本研究纳入 36 例高血压患者和 36 例健康对照者。采用酶联免疫吸附法测定血清凤凰素-14 和凤凰素-20 水平。
与对照组相比，高血压患者的血清凤凰素-14 和凤凰素-20 值明显降低（p<0.001）。凤凰素-14 水平与体重（r=-0.376；p<0.005）、体重指数（r=-0.407；p<0.001）、收缩压（r=-0.586；p<0.001）和舒张压（r=-0.319；p<0.01）呈负相关。血清凤凰素-20 与体重（r=-0.378；p<0.005）、体重指数（r=-0.383；p<0.005）、收缩压（r=-0.551；p<0.001）和舒张压（r=-0.306；p<0.01）呈负相关。我们使用受试者工作特征曲线分析比较了高血压患者中凤凰素-14 和凤凰素-20 水平的诊断价值。我们发现，凤凰素-14 值的曲线下面积为 0.87（截断值 404.7 ng/L，灵敏度 92%，特异性 72%），凤凰素-20 值的曲线下面积为 0.83（截断值 209.9 ng/L，灵敏度 86%，特异性 75%）。凤凰素-14 在预测高血压方面几乎与凤凰素-20 一样有效。
血清凤凰素-14 和凤凰素-20 可能与高血压的发病机制有关。我们的研究结果表明，血清凤凰素-14 和凤凰素-20 可能作为高血压诊断的一种新的生物标志物。
